Ad Spot

The future of Alzheimer’s treatment is here

The approval of the drug aducanumab on June 7 by the Food & Drug Administration marked a new phase in the fight against Alzheimer’s.

 

Aducanumab, known by its brand name of Aduhelm, is the first drug shown to slow – but not cure – Alzheimer’s disease and is the beginning of a completely new future for Alzheimer’s treatments. Historically, the first drug in a category invigorates the field, increases investments in new treatments and encourages greater innovation.

 

On June 16 the first patient outside of a clinical trial received the drug.  A 70-year-old Rhode Island man had an Aduhelm infusion at a medical facility.

 

Aduhelm works by removing amyloid from the brain. Amyloid is the protein that clumps into sticky brain plaques that are a hallmark of Alzheimer’s disease.  Aduhelm is administered intravenously (IV) via a 45- to 60-minute infusion every four weeks.

 

There has been much said of the cost for this drug.  The maker, Biogen, says it will be priced at $56,000 per year.  The Alzheimer’s Association

believes this amount is simply unacceptable. For many, this price will pose an insurmountable barrier to access, it complicates and jeopardizes sustainable access to this treatment, and may further deepen issues of health equity. The Association calls on Biogen to change this price.

 

We’re happy to have this new tool in the fight against Alzheimer’s.  If you or a loved one is experiencing memory changes, the Alzheimer’s Association strongly encourages speaking with a health care provider for a thorough evaluation, diagnosis and to discuss treatment options.  Visit us at alz.org or call our 24/7 helpline at 800-272-3900.

 

 

The Alzheimer’s Association leads the way to end Alzheimer’s and all other dementia – by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer’s and all other dementia. Visit alz.org or call 800-272-3900.

 

Scott Finley is media relations manager for the Alzheimer’s Association®.  He can be reached at scfinley@alz.org

 

Local

I-310 left southbound lane of the Hale Boggs Bridge closed Sunday

News

Abbeville man sentenced to federal prison for possessing firearm

News

TPSO seeks public’s help identifying subject

News

LDWF Agents investigating vessel fatality in Lafourche Parish

Edgard

Unanimous jury convicts Larry Dillion of violent crimes

News

Tangipahoa Parish Sheriff’s Office requests public’s help regarding recent shooting

News

Ponchatoula man sentenced for child sexual abuse material; possessed thousands of images

News

LDWF finds illegal oyster harvester in Lafourche Parish

News

SJSO calls for service 07/22

LaPlace

SJSO arrest reports 7/16-7/21

News

Louisiana Private Recreational Red Snapper Landing Estimates Through July 11, 2021

News

Louisiana 211 launches Opioid Crisis Referral and Crisis Texting Program: Growing concern over skyrocketing numbers of opioid fatalities

News

Tallulah man sentenced for trafficking methamphetamine

News

Convicted felon sentenced to more prison time

Local

SCSO seeks public’s help identifying suspects

News

Special enrollment period announced for Medicare Beneficiaries

Local

SCSO arrest reports 07/22

News

New Orleans man charged with drug trafficking offenses

News

SJSO calls for service 07/21

News

Felon indicted on federal gun charges

Local

Des Allemands man sentenced to ten years for aggravated criminal damage to property

News

Marksville Man Arrested for Possession of Child Sex Abuse Material

News

FBI and JPSO requesting the public’s assistance to identify the suspect from a Capital One Bank robbery

News

Historic $26 Billion Agreement with Opioid Distributors/Manufacturer Announced by AG Jeff Landry